Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Cornelissen

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2021
Poziotinib in Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 TrialXiuning Le, Robin Cornelissen, Marina Garassino, et al.
JTCVS Techniques|July 28, 2021
Virtual reality and artificial intelligence for 3-dimensional planning of lung segmentectomiesAmir H Sadeghi, Alexander P W M Maat, Yannick J H J Taverne, et al.
The Lancet. Oncology|June 7, 2024
Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 studyJoachim G Aerts, Robert Belderbos, Paul Baas, et al.
Translational Lung Cancer Research|August 25, 2021
Defining oligometastatic non-small cell lung cancer: concept versus biology, a literature reviewJill F Mentink, Marthe S Paats, Daphne W Dumoulin, et al.
American Journal of Respiratory and Critical Care Medicine|December 15, 2015
Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural MesotheliomaRobin Cornelissen, Joost P J J Hegmans, Alexander P W M Maat, et al.
JTO Clinical and Research Reports|May 23, 2022
Implementing Lung Cancer Screening in Europe: Taking a Systems ApproachSuzanne Wait, Arturo Alvarez-Rosete, Tasnime Osama, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 2020
High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patientsLuca Cantini, Federica Pecci, Daan P Hurkmans, et al.
Cellular Oncology (Dordrecht, Netherlands)|June 4, 2017
Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short reportNick Beije, Jaco Kraan, Michael A den Bakker, et al.
European Journal of Cancer (Oxford, England : 1990)|July 14, 2022
Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesotheliomaDaphne W Dumoulin, Luca Cantini, Robin Cornelissen, et al.
Oncoimmunology|December 8, 2018
Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapyLisanne Noordam, Margaretha E H Kaijen, Koen Bezemer, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2021
Poziotinib in Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 TrialXiuning Le, Robin Cornelissen, Marina Garassino, et al.
JTCVS Techniques|July 28, 2021
Virtual reality and artificial intelligence for 3-dimensional planning of lung segmentectomiesAmir H Sadeghi, Alexander P W M Maat, Yannick J H J Taverne, et al.
The Lancet. Oncology|June 7, 2024
Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 studyJoachim G Aerts, Robert Belderbos, Paul Baas, et al.
Translational Lung Cancer Research|August 25, 2021
Defining oligometastatic non-small cell lung cancer: concept versus biology, a literature reviewJill F Mentink, Marthe S Paats, Daphne W Dumoulin, et al.
American Journal of Respiratory and Critical Care Medicine|December 15, 2015
Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural MesotheliomaRobin Cornelissen, Joost P J J Hegmans, Alexander P W M Maat, et al.
JTO Clinical and Research Reports|May 23, 2022
Implementing Lung Cancer Screening in Europe: Taking a Systems ApproachSuzanne Wait, Arturo Alvarez-Rosete, Tasnime Osama, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 2020
High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patientsLuca Cantini, Federica Pecci, Daan P Hurkmans, et al.
Cellular Oncology (Dordrecht, Netherlands)|June 4, 2017
Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short reportNick Beije, Jaco Kraan, Michael A den Bakker, et al.
European Journal of Cancer (Oxford, England : 1990)|July 14, 2022
Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesotheliomaDaphne W Dumoulin, Luca Cantini, Robin Cornelissen, et al.
Oncoimmunology|December 8, 2018
Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapyLisanne Noordam, Margaretha E H Kaijen, Koen Bezemer, et al.
Pageof 6